LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Search

TransMedics Group Inc

Închisă

SectorSănătate

129.66 -7.32

Rezumat

Modificarea prețului

24h

Curent

Minim

128.48

Maxim

136.46

Indicatori cheie

By Trading Economics

Venit

81M

105M

Vânzări

17M

161M

P/E

Medie Sector

57.874

66.845

Marjă de profit

65.551

Angajați

898

EBITDA

-916K

32M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+13.37% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

422M

5B

Deschiderea anterioară

136.98

Închiderea anterioară

129.66

Sentimentul știrilor

By Acuity

50%

50%

154 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

TransMedics Group Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2025, 19:15 UTC

Principalele dinamici ale pieței

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Comparație

Modificare preț

TransMedics Group Inc Așteptări

Obiectiv de preț

By TipRanks

13.37% sus

Prognoză pe 12 luni

Medie 158.8 USD  13.37%

Maxim 190 USD

Minim 115 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruTransMedics Group Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

8

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

92.43 / 94.18Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

154 / 351 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat